Q&A with Chris Meissner, Meissner Filtration Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Chris Meissner, Meissner Filtration Products
A Q&A with Chris Meissner, president of Meissner Filtration Products, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 3, pp. 88

PharmTech:



Do you see a new industry trend emerging?

Meissner:

There are many new industry trends, but very few have broad appeal that haven't already been discussed at some length. One trend that continues to be worth watching closely is how the industry continues to evolve as it faces a shrinking pipeline of promising new drugs, while also facing escalating R&D costs and increasing regulatory scrutiny. In recent years, the trend has been to partner with emerging biotechnology companies. As profitable drugs move off patent, companies are taking a second look at competing with generic competition by tackling that competition head on. They're investing in more efficient processes and, in some cases, even acquiring generic drug manufacturing companies. Key suppliers will also be expected to evolve and will be relied on to bring core competencies to bear more economically than in-house-derived solutions.

PharmTech:

How will the industry remain innovative as it reduces spending on research?

Meissner:

Spending less money on research actually increases the need for innovation rather than dampening it. The desire to fund only those projects that have the best chance of commercial success has always been high, but differentiating which of those projects are most likely to succeed remains a very difficult task. Additionally, the path to success with almost every project will likely be challenged at various times by obstacles that are best overcome with innovation.

Smaller, dynamic biotechnology firms have always relied on key suppliers to assist them with innovative solutions to overcome obstacles such as process bottlenecks. Now pharmaceutical companies of every size, many of whom have historically been vertically integrated from R&D through manufacturing, are increasingly relying on partners to conceive cost-effective solutions, effectively outsourcing many challenges. Our customers increasingly rely on us to enhance their R&D and manufacturing efficiency thereby stretching budgets as far as possible.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here